BC Week In Review | Dec 16, 2016
Financial News

GI Dynamics completes private placement

GI Dynamics raised A$1.5 million ($1.1 million) through the sale of 69.9 million CHESS Depositary Interests (CDI) at A$0.02 in a private placement with sophisticated and professional investors and existing investors. Each CDI represents a...
BC Week In Review | Jul 25, 2016
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial final data

Final data from 320 inadequately controlled obese patients with Type II diabetes in the modified intent-to-treat (mITT) population of the double-blind, U.S. pivotal ENDO trial showed that EndoBarrier Gastrointestinal Liner reduced mean HbA1c from baseline...
BC Week In Review | Mar 21, 2016
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial data

Top-line data from the double-blind, U.S. pivotal ENDO trial in 325 inadequately controlled obese patients with Type II diabetes showed that EndoBarrier Gastrointestinal Liner missed the co-primary endpoint of reducing mean HbA1c from baseline to...
BC Week In Review | Sep 28, 2015
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial discontinued

GI Dynamics discontinued the double-blind, sham-controlled, U.S. pivotal ENDO trial of EndoBarrier Gastrointestinal Liner following discussions with FDA regarding the trial’s possible resumption. In March, FDA placed a clinical hold on enrollment in the trial...
BC Week In Review | Apr 13, 2015
Clinical News

EndoBarrier: Pivotal trial hold

Last month, FDA placed a clinical hold on enrollment in the double-blind, sham-controlled, U.S. pivotal ENDO trial of EndoBarrier Gastrointestinal Liner due to 4 cases of hepatic abscess among the 325 obese Type II diabetics...
BC Week In Review | Sep 1, 2014
Company News

GI Dynamics management update

GI Dynamics Inc. (ASX:GID), Lexington, Mass   Business: Endocrine/Metabolic   Hired: Michael Dale as president, CEO and a director, effective Sept. 18, formerly president, CEO and chairman of ATS Medical Inc., which Medtronic Inc. acquired;...
BC Week In Review | Jul 15, 2013
Financial News

GI Dynamics completes private placement

GI Dynamics Inc. (ASX:GID), Lexington, Mass.   Business: Endocrine/Metabolic   Date completed: 7/1/13   Type: Private placement   Raised: A$38.1 million ($35 million)   Shares: 71.8 million   Price: A$0.53   Shares after offering: 359.2...
BC Week In Review | Jul 15, 2013
Financial News

GI Dynamics proposes rights offering

GI Dynamics Inc. (ASX:GID), Lexington, Mass.   Business: Endocrine/Metabolic   Date announced: 7/2/13   Type: Rights offering   To be raised: Up to A$2.5 million ($2.3 million)   Shares: TBD   Price: A$0.53   Shares...
BioCentury | Jul 15, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)....
BC Extra | Jul 3, 2013
Financial News

GI Dynamics raises A$38.1 million

GI Dynamics Inc. (ASX:GID) raised A$38.1 million ($35 million) through the sale of 71.8 million CHESS Depository Interests (CDIs) at A$0.53 in a private placement. Each CDI represents a fifth of a common share. GI...
Items per page:
1 - 10 of 34
BC Week In Review | Dec 16, 2016
Financial News

GI Dynamics completes private placement

GI Dynamics raised A$1.5 million ($1.1 million) through the sale of 69.9 million CHESS Depositary Interests (CDI) at A$0.02 in a private placement with sophisticated and professional investors and existing investors. Each CDI represents a...
BC Week In Review | Jul 25, 2016
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial final data

Final data from 320 inadequately controlled obese patients with Type II diabetes in the modified intent-to-treat (mITT) population of the double-blind, U.S. pivotal ENDO trial showed that EndoBarrier Gastrointestinal Liner reduced mean HbA1c from baseline...
BC Week In Review | Mar 21, 2016
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial data

Top-line data from the double-blind, U.S. pivotal ENDO trial in 325 inadequately controlled obese patients with Type II diabetes showed that EndoBarrier Gastrointestinal Liner missed the co-primary endpoint of reducing mean HbA1c from baseline to...
BC Week In Review | Sep 28, 2015
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial discontinued

GI Dynamics discontinued the double-blind, sham-controlled, U.S. pivotal ENDO trial of EndoBarrier Gastrointestinal Liner following discussions with FDA regarding the trial’s possible resumption. In March, FDA placed a clinical hold on enrollment in the trial...
BC Week In Review | Apr 13, 2015
Clinical News

EndoBarrier: Pivotal trial hold

Last month, FDA placed a clinical hold on enrollment in the double-blind, sham-controlled, U.S. pivotal ENDO trial of EndoBarrier Gastrointestinal Liner due to 4 cases of hepatic abscess among the 325 obese Type II diabetics...
BC Week In Review | Sep 1, 2014
Company News

GI Dynamics management update

GI Dynamics Inc. (ASX:GID), Lexington, Mass   Business: Endocrine/Metabolic   Hired: Michael Dale as president, CEO and a director, effective Sept. 18, formerly president, CEO and chairman of ATS Medical Inc., which Medtronic Inc. acquired;...
BC Week In Review | Jul 15, 2013
Financial News

GI Dynamics completes private placement

GI Dynamics Inc. (ASX:GID), Lexington, Mass.   Business: Endocrine/Metabolic   Date completed: 7/1/13   Type: Private placement   Raised: A$38.1 million ($35 million)   Shares: 71.8 million   Price: A$0.53   Shares after offering: 359.2...
BC Week In Review | Jul 15, 2013
Financial News

GI Dynamics proposes rights offering

GI Dynamics Inc. (ASX:GID), Lexington, Mass.   Business: Endocrine/Metabolic   Date announced: 7/2/13   Type: Rights offering   To be raised: Up to A$2.5 million ($2.3 million)   Shares: TBD   Price: A$0.53   Shares...
BioCentury | Jul 15, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)....
BC Extra | Jul 3, 2013
Financial News

GI Dynamics raises A$38.1 million

GI Dynamics Inc. (ASX:GID) raised A$38.1 million ($35 million) through the sale of 71.8 million CHESS Depository Interests (CDIs) at A$0.53 in a private placement. Each CDI represents a fifth of a common share. GI...
Items per page:
1 - 10 of 34